drugset / Trial / NCT03692403

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

NCT03692403

Phase 2 Completed 22 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain

Timeline

Start
2018-12-26
Primary completion
2022-02-14
Completion
2022-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Quinagolide Other / unclassified 360 ug Other
Subject Quinagolide Other / unclassified 720 ug Other
Subject Quinagolide Other / unclassified 1080 ug Other

Indications